TMC435 for the treatment of chronic hepatitis C

Expert Opinion on Investigational Drugs

Volumn 21, Issue 8, 2012, Pages 1193-1209

  Tanwar, Sudeep ^a   Trembling, Paul M ^a   Dusheiko, Geoffrey M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

hepatitis C; pegylated interferon; protease inhibitor; ribavirin; TMC435

Indexed keywords

ACETYLSALICYLIC ACID; BOCEPREVIR; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; ESCITALOPRAM; METHADONE; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON; RIBAVIRIN; RIFAMPICIN; SIMEPREVIR; TELAPREVIR;

ANEMIA; ANTIVIRAL ACTIVITY; APPETITE; ASTHENIA; BONE PAIN; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; FATIGUE; FEVER; GENE MUTATION; GENOTYPE; HEADACHE; HEALTH CARE QUALITY; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; IN VITRO STUDY; INFLUENZA; INSOMNIA; MYALGIA; NAUSEA; PRURITUS; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INTERFERONS; RIBAVIRIN; SULFONAMIDES;

EID: 84863702794     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.690392     Document Type: Review

References (53)

1. WHO. Hepatitis C: global prevalence (update). Wkly Epidemiol Rec 1999;49(74):425-7
2. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol 1999;31(Suppl 1):25-30 (Pubitemid 30002687)
3. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9(3):383-98, vi (Pubitemid 40968202)
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65 (Pubitemid 32913521)
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
6. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361(6):580-93
7. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010;51(2):388-97
8. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461(7262):399-401
9. Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285(5424):110-13 (Pubitemid 29307577)
10. Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov 2002;1(11):911-16 (Pubitemid 37361585)
11. Tomei L, Altamura S, Paonessa G, et al. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antivir Chem Chemother 2005;16(4):225-45 (Pubitemid 41139709)
12. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345(1):41-52 (Pubitemid 32634271)
13. Blight KJ, Kolykhalov AA, Reed KE, et al. Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets. Antivir Ther 1998;3(Suppl 3):71-81 (Pubitemid 28528323)
14. Tomei L, Failla C, Santolini E, et al. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993;67(7):4017-26 (Pubitemid 23180726)
15. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
16. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365(11):1014-24
17. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364(25):2417-28
18. Pawlotsky JM. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 2011;140(3):746-54
19. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-16
20. Raboisson P, de Kock H, Rosenquist A, et al. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett 2008;18(17):4853-8 A concise review of the chemistry of TMC435 and other macrocyclic protease.
21. Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antivir Res 2006;69(3):129-41 (Pubitemid 43247333)
22. Soriano V, Perelson AS, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 2008;62(1):1-4 (Pubitemid 351865869)
23. Cubero M, Esteban JI, Otero T, et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008;370(2):237-45 (Pubitemid 350192568)
24. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132(5):1767-77 (Pubitemid 46677938)
25. Cummings MD, Lindberg J, Lin TI, et al. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew Chem Int Ed Engl 2010;49(9):1652-5
26. Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discovery--an underexploited structural class. Nat Rev Drug Discov 2008;7(7):608-24 (Pubitemid 351927725)
27. Tsantrizos YS. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic. Biopolymers 2004;76(4):309-23 (Pubitemid 39468254)
28. Lin TI, Lenz O, Fanning G, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009;53(4):1377-85
29. Lenz O, Berke JM, de Kock H, et al. Combination of TMC435 with two novel NS5B inhibitors increases anti-HCV activity and results in a higher genetic barrier in vitro. J Hepatol 2010;52(Suppl 1):S295-S96
30. Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010;54(5):1878-87
31. Sekar V, Verloes R, Meyvisch P, et al. Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers. J Hepatol 2010;52(Suppl 1):S416
32. Sekar V, Vis P, Lenz O, et al. Pharmacokinetic-pharmacodynamic (PK-PD) analyses of TMC435 in treatment-naive hepatitis C (HCV)-infected patients in the OPERA-1 study. J Hepatol 2010;52(Suppl 1):S416
33. Sekar V, Simion A, Peeters M, et al. Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment. J Hepatol 2011;54(Suppl 1):S193
34. Beumont-Mauviel M, Simion A, De Smedt G, et al. The pharmacokinetic interaction between the investigational HCV NS3/4A protease inhibitor TMC435 and escitalopram. AASLD 2011 Annual Meeting; 2011
35. Beumont-Mauviel M, De Smedt G, Peeters M, et al. The pharmacokinetic interaction between the investigational NS3-4A HCV protease inhibitor TMC435 and methadone. AASLD 2011 Annual Meetng; 2011
36. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010;138(3):913-21 This is a comprehensive summary of the Phase I TMC435 trial.
37. Manns M, Reesink H, Berg T, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011;16(7):1021-33 This is a comprehensive summary of the OPERA-1 TMC435 trial.
38. Lenz O, de Bruijne J, Vijgen L, et al. Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PEGIFNalpha-2a/ribavirin. J Hepatol 2011;54(Suppl 1):S482-S83
39. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2 to 6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012. [Epub ahead of print]
40. Huisman M, Snoeys J, Monbaliu J, et al. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. AASLD 2010; 2010
41. Fried M, Buti M, Dore GJ, et al. TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIB study. [Epub ahead of print] AASLD 2011 Annual Meetng; 2011
42. Aerssens J, Fanning G, Scholliers A, et al. Impact of IL28B genotype and pretreatment serum IP-10 in treatment-naive genotype-1 HCV patients treated with TMC435 in combination with peginterferona-2a and ribavirin in PILLAR study. J Hepatol 2011;54(Suppl 1):S5-6
43. Lenz O, Fevery B, Vijgen L, et al. TMC435 in combination with peginterferon alpha-2a/ribavirin in treatment-naive patients infected with HCV genotype 1: virology analysis of the PILLAR study. AASLD 2011 Annual Meetng; 2011
44. Marcellin P, Reesink H, Berg T, et al. Antiviral activity and safety of TMC435 combined with peginterferon alpha-2a and ribavirin in patients with genotype 1 hepatitis C infection who failed previous IFN-based therapy. J Hepatol 2009;50(Suppl 1):S385
45. Zeuzem S, Foster GR, Fried MW, et al. The ASPIRE trial: TMC435 in treatment-experienced patients with genotype-1 HCV infection who have failed previous PEGIFN/RBV treatment. J Hepatol 2011;54(Suppl 1):S546
46. Lawitz E, Lalezari JP, Hassanein T, et al. Once-Daily PSI-7977 Plus Peg/RBV in Treatment-naive Patients with HCV GT1: Robust End of Treatment Response Rates are Sustained Post-treatment. AASLD 2011 Annual Meetng; 2011
47. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. J Hepatol 2011;54(Suppl 1):S4
48. Halfon P, Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int 2012;32:79-87
49. Dusheiko GM, Jacobs MG. Perspectives on the management of chronic hepatitis B and C. Expert Rev Anti Infect Ther 2009;7(3):243-7
50. Ciesek S, von Hahn T, Manns MP. Second-wave protease inhibitors: choosing an heir. Clin Liver Dis 2011;15(3):597-609
51. Manns MP, Bourliere M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011;54(6):1114-22
52. Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients. J Hepatol 2011;55(5):972-9
53. Liverton NJ, Carroll SS, Dimuzio J, et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother 2010;54(1):305-11